Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INKmune |
Synonyms | |
Therapy Description |
INKmune is a replication incompetent tumor cell product that potentially generates tumor-induced memory-like NK cells, leading to enhanced toxicity against tumor cells (Blood (2022) 140 (Supplement 1): 4590–4591). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INKmune | INKmune is a replication incompetent tumor cell product that potentially generates tumor-induced memory-like NK cells, leading to enhanced toxicity against tumor cells (Blood (2022) 140 (Supplement 1): 4590–4591). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05933070 | Phase I | INKmune | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL) | Terminated | GRC | GBR | 0 |
NCT06056791 | Phase Ib/II | INKmune | Study of INKmune in Patients With mCRPC (CaRe Prostate) (CaRe) | Recruiting | USA | 0 |